Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib in Relapsed/Refractory Small Cell Lung Cancer
NCT03216343Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Nov 2017
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of chiauranib in small cell lung cancer (SCLC), sponsored by Akeso, Inc. Primary endpoint: Objective Response Rate up to 24 weeks. Started Nov 2017; status: completed.
02
Drugs
chiauranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03216343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03216343.